개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 한국생체재료학회 생체재료학회지 생체재료학회지 제27권
- 발행연도
- 2023.3
- 수록면
- 428 - 448 (21page)
- DOI
- 10.1186/s40824-023-00342-5
이용수
초록· 키워드
오류제보하기
Obesity, a serious threat to public health, is linked to chronic metabolic complications including insulin resistance, type-2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD). Current obesity medications are challenged by poor effectiveness, poor patient compliance, and potential side effects. Verapamil is an inhibitor of L-type calcium channels, FDA-approved for the treatment of hypertension. We previously investigated the effect of verapamil on modulating autophagy to treat obesity-associated lipotoxicity. This study aims to develop a verapamil transdermal patch and to evaluate its anti-obesity effects.Verapamil is loaded in biomimetic vascular bundle-like carboxymethyl pullulan-based supramolecular hydrogel patches cross-linked with citric acid and glycerol linkages (CLCMP). The investigation was then carried out to determine the therapeutic effect of verapamil-loaded CLCMP (Vera@CLCMP) on diet-induced obese mice.Vera@CLCMP hydrogel patches with hierarchically organized and anisotropic pore structures not only improved verapamil bioavailability without modifying its chemical structure but also enhanced verapamil release through the stratum corneum barrier. Vera@CLCMP patches exhibit low toxicity and high effectiveness at delivering verapamil into the systemic circulation through the dermis in a sustained manner. Specifically, transdermal administration of this patch into diet-induced obese mice drastically improved glucose tolerance and insulin sensitivity and alleviated metabolic derangements associated with MAFLD. Furthermore, we uncovered a distinct molecular mechanism underlying the anti-obesity effects associated with the hepatic NLR family pyrin domain-containing 3 (NLRP3) inflammasome and autophagic clearance by the vera@CLCMP hydrogel patches.The current study provides promising drug delivery platforms for long-term family treatment of chronic diseases, including obesity and metabolic dysfunctions.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Clinical and Molecular Hepatology
2021 .01
-
The Role of T Cells in Obesity-Associated Inflammation and Metabolic Disease
Immune Network
2022 .02
-
Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Gut and Liver
2021 .01
-
Swellable microneedle patches for transdermal protein drug delivery
한국실험동물학회 학술발표대회 논문집
2017 .02
-
Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
Gut and Liver
2022 .07
-
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Clinical and Molecular Hepatology
2023 .04
-
Effect of Korean Red Ginseng on metabolic syndrome
Journal of Ginseng Research
2021 .05
-
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Diabetes and Metabolism Journal
2023 .03
-
Associations among the Degree of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, Degree of Obesity in Children, and Parental Obesity
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Severe Obesity in Children and Adolescents: Metabolic Effects, Assessment, and Treatment
Journal of Obesity & Metabolic Syndrome
2021 .12
-
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Clinical and Molecular Hepatology
2024 .01
-
Antinociceptive and anti-inflammatory effects of N-acetylcysteine and verapamil in Wistar rats
The Korean Journal of Pain
2019 .01
-
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Clinical and Molecular Hepatology
2022 .04
-
Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2023 .03
-
Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism
Immune Network
2025 .02
-
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Clinical and Molecular Hepatology
2023 .04
-
The Influence of Obesity and Metabolic Health on Vascular Health
Endocrinology and Metabolism
2022 .02
-
비만 약물 치료의 최신 지견
대한내과학회지
2018 .01
-
Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology
2024 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0